RUNX2 and acute myeloid leukemia: Some level of residual RUNX activity appears to be required, however, since deletion of Runx1 eliminates the ability of CBFB::MYH11 to induce AML (99, 100), while overexpression of Runx2 accelerates leukemogenesis (101, 102).